Enrique F Schisterman1, Robert M Silver2, Laurie L Lesher2, David Faraggi3, Jean Wactawski-Wende4, Janet M Townsend5, Anne M Lynch6, Neil J Perkins7, Sunni L Mumford7, Noya Galai3. 1. Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA. Electronic address: schistee@mail.nih.gov. 2. Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, School of Medicine, Salt Lake City, UT, USA. 3. Department of Statistics, University of Haifa, Haifa, Israel. 4. Department of Social and Preventive Medicine, University at Buffalo, Buffalo, NY, USA. 5. Department of Family, Community and Rural Health, Commonwealth Medical College, Scranton, PA, USA. 6. Department of Obstetrics and Gynecology, University of Colorado, Denver, CO, USA. 7. Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.
Abstract
BACKGROUND:Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses. METHODS: In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18-40 years who were attempting to become pregnant were recruited from four medical centres in the USA. Participants were stratified by eligibility criteria--the original stratum was restricted to women with one loss at less than 20 weeks' gestation during the previous year, whereas the expanded stratum included women with one to two previous losses, with no restrictions on gestational age or time of loss. Women were block-randomised by centre and eligibility stratum in a 1:1 ratio. Preconception-initiated daily low-dose aspirin (81 mg per day) plus folic acid was compared with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatment continued until 36 weeks' gestation. Participants, trial staff, and investigators were masked to the assigned treatment. The primary outcome was livebirth rate, which was analysed by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00467363. FINDINGS: Overall, 1228 women were recruited and randomly assigned between June 15, 2007, and July 15, 2011, 1078 of whom completed the trial and were included in the analysis (535 in the low-dose aspirin group and 543 in the placebo group). 309 (58%) women in the low-dose aspirin group had livebirths, compared with 286 (53%) in the placebo group (p=0·0984; absolute difference in livebirth rate 5·09% [95% CI -0·84 to 11·02]). Pregnancy loss occurred in 68 (13%) women in the low-dose aspirin group, compared with 65 (12%) women in the placebo group (p=0·7812). In the original stratum, 151 (62%) of 242 women in the low-dose aspirin group had livebirths, compared with 133 (53%) of 250 in the placebo group (p=0·0446; absolute difference in livebirth rate 9·20% [0·51 to 17·89]). In the expanded stratum, 158 (54%) of 293 women in the low-dose aspirin group and 153 (52%) of 293 in the placebo group had livebirths (p=0·7406; absolute difference in livebirth rate 1·71% [-6·37 to 9·79]). Major adverse events were similar between treatment groups. Low-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associated with pregnancy loss. INTERPRETATION:Preconception-initiated low-dose aspirin was not significantly associated with livebirth or pregnancy loss in women with one to two previous losses. However, higher livebirth rates were seen in women with a single documented loss at less than 20 weeks' gestation during the previous year. Low-dose aspirin is not recommended for the prevention of pregnancy loss. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development (US National Institutes of Health).
RCT Entities:
BACKGROUND: Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses. METHODS: In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18-40 years who were attempting to become pregnant were recruited from four medical centres in the USA. Participants were stratified by eligibility criteria--the original stratum was restricted to women with one loss at less than 20 weeks' gestation during the previous year, whereas the expanded stratum included women with one to two previous losses, with no restrictions on gestational age or time of loss. Women were block-randomised by centre and eligibility stratum in a 1:1 ratio. Preconception-initiated daily low-dose aspirin (81 mg per day) plus folic acid was compared with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatment continued until 36 weeks' gestation. Participants, trial staff, and investigators were masked to the assigned treatment. The primary outcome was livebirth rate, which was analysed by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00467363. FINDINGS: Overall, 1228 women were recruited and randomly assigned between June 15, 2007, and July 15, 2011, 1078 of whom completed the trial and were included in the analysis (535 in the low-dose aspirin group and 543 in the placebo group). 309 (58%) women in the low-dose aspirin group had livebirths, compared with 286 (53%) in the placebo group (p=0·0984; absolute difference in livebirth rate 5·09% [95% CI -0·84 to 11·02]). Pregnancy loss occurred in 68 (13%) women in the low-dose aspirin group, compared with 65 (12%) women in the placebo group (p=0·7812). In the original stratum, 151 (62%) of 242 women in the low-dose aspirin group had livebirths, compared with 133 (53%) of 250 in the placebo group (p=0·0446; absolute difference in livebirth rate 9·20% [0·51 to 17·89]). In the expanded stratum, 158 (54%) of 293 women in the low-dose aspirin group and 153 (52%) of 293 in the placebo group had livebirths (p=0·7406; absolute difference in livebirth rate 1·71% [-6·37 to 9·79]). Major adverse events were similar between treatment groups. Low-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associated with pregnancy loss. INTERPRETATION: Preconception-initiated low-dose aspirin was not significantly associated with livebirth or pregnancy loss in women with one to two previous losses. However, higher livebirth rates were seen in women with a single documented loss at less than 20 weeks' gestation during the previous year. Low-dose aspirin is not recommended for the prevention of pregnancy loss. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development (US National Institutes of Health).
Authors: M Tulppala; M Marttunen; V Söderstrom-Anttila; T Foudila; K Ailus; T Palosuo; O Ylikorkala Journal: Hum Reprod Date: 1997-07 Impact factor: 6.918
Authors: Elizabeth A DeVilbiss; Sunni L Mumford; Lindsey A Sjaarda; Matthew T Connell; Keewan Kim; James L Mills; Robert M Silver; Enrique F Schisterman Journal: Am J Obstet Gynecol Date: 2019-02-23 Impact factor: 8.661
Authors: Sunni L Mumford; Rebecca A Garbose; Keewan Kim; Kerri Kissell; Daniel L Kuhr; Ukpebo R Omosigho; Neil J Perkins; Noya Galai; Robert M Silver; Lindsey A Sjaarda; Torie C Plowden; Enrique F Schisterman Journal: Lancet Diabetes Endocrinol Date: 2018-05-31 Impact factor: 32.069
Authors: Lindsay D Levine; Tiffany L Holland; Keewan Kim; Lindsey A Sjaarda; Sunni L Mumford; Enrique F Schisterman Journal: Can J Physiol Pharmacol Date: 2018-12-18 Impact factor: 2.273
Authors: Stefanie N Hinkle; Sunni L Mumford; Katherine L Grantz; Robert M Silver; Emily M Mitchell; Lindsey A Sjaarda; Rose G Radin; Neil J Perkins; Noya Galai; Enrique F Schisterman Journal: JAMA Intern Med Date: 2016-11-01 Impact factor: 21.873
Authors: Rose G Radin; Lindsey A Sjaarda; Neil J Perkins; Robert M Silver; Zhen Chen; Laurie L Lesher; Noya Galai; Jean Wactawski-Wende; Sunni L Mumford; Enrique F Schisterman Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958
Authors: Rose G Radin; Sunni L Mumford; Robert M Silver; Laurie L Lesher; Noya Galai; David Faraggi; Jean Wactawski-Wende; Janet M Townsend; Anne M Lynch; Hyagriv N Simhan; Lindsey A Sjaarda; Neil J Perkins; Shvetha M Zarek; Karen C Schliep; Enrique F Schisterman Journal: J Clin Invest Date: 2015-08-17 Impact factor: 14.808